TGFBR2 and neoplasm: TGFBR2 behaves as an oncogene and TGFBR2 mutations were documented in up to 40% of patients with CRC, leading to chemotherapy resistance and immunosuppression, and consequently promoting tumor angiogenesis [29,30].